Caxton Associates LLP Makes New Investment in Zoetis Inc. $ZTS

Key Points

• Caxton Associates LLP has initiated a new investment in Zoetis Inc. by acquiring 5,647 shares valued at approximately $930,000.
• Zoetis reported a 4.2% year-over-year increase in quarterly revenue, totaling $2.46 billion, and exceeded earnings expectations with an EPS of $1.76.
• Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy" and an average price target of $200.88.

Caxton Associates LLP bought a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 5,647 shares of the company's stock, valued at approximately $930,000.

Several other large investors also recently bought and sold shares of ZTS. Nuveen LLC purchased a new stake in Zoetis during the 1st quarter worth approximately $616,375,000. Sarasin & Partners LLP purchased a new stake in Zoetis during the 1st quarter worth approximately $339,111,000. Mackenzie Financial Corp grew its position in Zoetis by 4,158.3% during the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock worth $300,481,000 after purchasing an additional 1,782,110 shares during the last quarter. GAMMA Investing LLC grew its position in Zoetis by 14,731.3% during the 1st quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock worth $289,666,000 after purchasing an additional 1,747,423 shares during the last quarter. Finally, Polen Capital Management LLC grew its position in Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Stock Performance

ZTS opened at $149.45 on Thursday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a fifty day moving average price of $152.70 and a 200 day moving average price of $157.56. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The stock has a market cap of $66.24 billion, a P/E ratio of 25.72, a P/E/G ratio of 2.40 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. During the same period in the previous year, the business posted $1.56 EPS. The business's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Analyst Ratings Changes

ZTS has been the topic of several recent research reports. Argus reaffirmed a "buy" rating and issued a $190.00 price objective on shares of Zoetis in a report on Tuesday. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Piper Sandler upped their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Finally, Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.